7.46
前日終値:
$7.36
開ける:
$7.4
24時間の取引高:
291.59K
Relative Volume:
0.26
時価総額:
$211.97M
収益:
$157.75M
当期純損益:
$-29.73M
株価収益率:
-6.431
EPS:
-1.16
ネットキャッシュフロー:
$-21.00M
1週間 パフォーマンス:
+5.07%
1か月 パフォーマンス:
+21.10%
6か月 パフォーマンス:
-50.07%
1年 パフォーマンス:
-54.76%
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
名前
Arcturus Therapeutics Holdings Inc
セクター
電話
(858) 900-2660
住所
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
ARCT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ARCT
Arcturus Therapeutics Holdings Inc
|
7.46 | 209.13M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-23 | 開始されました | Roth Capital | Buy |
| 2025-10-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-10-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-09-04 | 再開されました | H.C. Wainwright | Buy |
| 2025-05-28 | 開始されました | Scotiabank | Sector Outperform |
| 2025-01-28 | 開始されました | BTIG Research | Buy |
| 2024-08-12 | 開始されました | Leerink Partners | Outperform |
| 2023-12-13 | 開始されました | Canaccord Genuity | Buy |
| 2023-07-24 | 開始されました | William Blair | Outperform |
| 2023-05-11 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | 再開されました | Wells Fargo | Overweight |
| 2022-11-10 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | アップグレード | Citigroup | Neutral → Buy |
| 2022-11-02 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-08-10 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-05-11 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-01-31 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | ダウングレード | Goldman | Neutral → Sell |
| 2021-08-10 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-06-25 | 再開されました | Goldman | Neutral |
| 2021-06-21 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-02-17 | ダウングレード | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | 開始されました | Wells Fargo | Overweight |
| 2020-12-29 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-12-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | ダウングレード | ROTH Capital | Buy → Sell |
| 2020-12-08 | 繰り返されました | B. Riley Securities | Buy |
| 2020-12-07 | 繰り返されました | B. Riley Securities | Buy |
| 2020-10-26 | 開始されました | Barclays | Overweight |
| 2020-10-06 | 開始されました | Citigroup | Buy |
| 2020-08-26 | 開始されました | Piper Sandler | Overweight |
| 2020-07-30 | 再開されました | ROTH Capital | Buy |
| 2020-07-16 | 開始されました | Raymond James | Outperform |
| 2020-07-13 | 開始されました | B. Riley FBR | Buy |
| 2020-06-09 | ダウングレード | WBB Securities | Buy → Hold |
| 2020-02-11 | 開始されました | Robert W. Baird | Outperform |
| 2020-02-07 | 開始されました | Guggenheim | Buy |
| 2020-02-06 | 開始されました | Guggenheim | Buy |
| 2019-04-05 | 開始されました | H.C. Wainwright | Buy |
| 2018-09-20 | アップグレード | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Arcturus Therapeutics Holdings Inc (ARCT) 最新ニュース
Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by Roth Mkm - MarketBeat
Roth/MKM initiates coverage on Arcturus Therapeutics stock with Buy rating By Investing.com - Investing.com India
Stifel Initiates Arcturus Therapeutics(ARCT.US) With Buy Rating, Announces Target Price $20 - 富途资讯
Roth/MKM initiates coverage on Arcturus Therapeutics stock with Buy rating - Investing.com
Arcturus wins FDA fast track status for influenza vaccine - MSN
Price-Driven Insight from (ARCT) for Rule-Based Strategy - Stock Traders Daily
Market Review: How liquid is Arcturus Therapeutics Holdings Inc stockJuly 2025 Summary & Growth Focused Entry Point Reports - baoquankhu1.vn
Analysis Recap: Should value investors consider Arcturus Therapeutics Holdings Inc2025 Valuation Update & Fast Moving Market Watchlists - baoquankhu1.vn
Aug EndMonth: Should value investors consider Arcturus Therapeutics Holdings Inc2025 Market Overview & Risk Controlled Swing Alerts - baoquankhu1.vn
FEDERATED HERMES, INC. Reduces Stake in Arcturus Therapeutics Ho - GuruFocus
Does Arcturus Therapeutics (ARCT) JPM Conference Spotlight Clarify Its Long-Term Platform Credibility? - simplywall.st
Aug EndMonth: Should I hold or sell Arcturus Therapeutics Holdings Inc stock in 2025July 2025 Update & AI Powered Buy and Sell Recommendations - Bộ Nội Vụ
Arcturus Therapeutics Holdings (ARCT) Valuation Check As J.P. Morgan Healthcare Conference Presentation Nears - Yahoo Finance
Arcturus Therapeutics Maps Near-Term Milestones for CF mRNA Therapy, ARCT-810 at J.P. Morgan Conference - MarketBeat
ARCT: Advancing mRNA therapies for CF and OTC with strong data, regulatory focus, and solid funding - TradingView
Is Arcturus Therapeutics (ARCT) Using Its $500 Million Shelf to Redefine Capital Strategy? - Yahoo Finance
Ag Plus, Inc. - Ag Plus, Inc.
1 Under-$10 Stock Set to Surge as Much as 963% in 2026 - Yahoo Finance
Will Arcturus Therapeutics Holdings Inc. stock maintain momentum in 2025Portfolio Profit Report & AI Driven Stock Movement Reports - ulpravda.ru
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate - MSN
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Can Arcturus Therapeutics Holdings Inc. stock rebound after recent weaknessPortfolio Profit Report & Precise Entry and Exit Recommendations - Улправда
Is Arcturus Therapeutics Holdings Inc. stock positioned well for digital economyJuly 2025 Selloffs & Scalable Portfolio Growth Ideas - Улправда
Earnings Beat: Can Arcturus Therapeutics Holdings Inc. stock rebound after recent weaknessWeekly Earnings Recap & Real-Time Volume Surge Alerts - Улправда
Arcturus Therapeutics Holdings (ARCT): Analyst Ratings Suggest a Staggering 415% Upside Potential - DirectorsTalk Interviews
Citigroup Lowers Price Target for ARCT, Maintains Neutral Rating - GuruFocus
(ARCT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arcturus Therapeutics (NASDAQ:ARCT) Price Target Cut to $7.00 by Analysts at Citigroup - MarketBeat
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
UK Regulator OKs Arcturus Therapeutics' COVID-19 Booster Jab - MarketScreener
MHRA approves Kostaive mRNA COVID-19 vaccine - The Pharma Letter
What analysts say about Arcturus Therapeutics Holdings Inc stockStraddle and Strangle Trades & Investment Case Studies - earlytimes.in
Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Arcturus Therapeutics Holdings files for mixed shelf of up to $500 millionSEC filing - MarketScreener
Arcturus Therapeutics Files $500 Million Mixed Shelf - MarketScreener
Precision Trading with Arcturus Therapeutics Holdings Inc. (ARCT) Risk Zones - Stock Traders Daily
Arcturus Therapeutics (ARCT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: Unveiling A 446% Potential Upside - directorstalkinterviews.com
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Will Arcturus Therapeutics Holdings Inc. stock benefit from infrastructure spending2025 Volume Leaders & Risk Controlled Daily Trade Plans - Улправда
How strong is Arcturus Therapeutics Holdings Inc. stock balance sheetMarket Activity Report & Weekly Watchlist of Top Performers - Улправда
How Arcturus Therapeutics Holdings Inc. stock reacts to job market dataTrade Risk Assessment & Weekly High Return Stock Forecasts - Улправда
Why Arcturus Therapeutics Holdings Inc. stock could outperform in 2025Weekly Market Report & Daily Momentum Trading Reports - DonanımHaber
How supply chain issues affect Arcturus Therapeutics Holdings Inc. stockWeekly Trend Recap & AI Enhanced Market Trend Forecasts - DonanımHaber
Arcturus Therapeutics Holdings Inc. Announces Management Changes - marketscreener.com
Arcturus Therapeutics CFO Andy Sassine to leave company - marketscreener.com
Arcturus Therapeutics announces CFO transition and interim appointment By Investing.com - Investing.com Australia
Arcturus Therapeutics Announces CFO Departure and Replacement - TipRanks
Arcturus Therapeutics announces CFO departure and replacement - MSN
Arcturus Therapeutics announces CFO transition and interim appointment - Investing.com
Arcturus Therapeutics Announces CFO Departure and Interim Appointment - TradingView — Track All Markets
Arcturus Therapeutics Holdings Inc (ARCT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):